Cut-off Analysis of HLA-A and HLA-B/C Expression As a Potential Prognosticator of Favorable Survival in Patients With Metastatic Breast Cancer
Overview
Authors
Affiliations
Background/aim: Loss of differentiation of breast cancer cells in association with a down-regulated class I human leukocyte antigen (HLA) expression can lead to proliferation unhampered by cytotoxic T lymphocytes, which has been proven to be of prognostic relevance. The objective of this study was to determine the levels of HLA-A and HLA-B/C expression in metastatic breast cancer (MBC) cells and their usefulness for predicting 5-year survival.
Materials And Methods: This prospective double-blinded cohort study analyzed patients starting a new line of therapy for MBC. RT-qPCR was used to determine the levels of HLA-A and B/C expression in MBC cells and the mRNA-based tumor intrinsic subtype. Two receiver operating characteristic curves (ROC) were constructed in order to determine whether HLA-A and HLA-B/C expression levels can be used for predicting 5-year survival. Youden J points, and sensitivity and specificity optimized cut-off points were determined for both ROC curves.
Results: We enrolled 34 patients. The ROC curve for HLA-B/C had the highest AUC compared to HLA-A (0.55 vs. 0.42). High levels of HLA-A and HLA-B/C expression (40-ΔΔCT of 33.5 and 31.9, respectively) were highly specific (reaching 87.5% for HLA-A and even 100% specificity for HLA-B/C) yet insensitive for five-year survival in our study.
Conclusion: High expression of certain class I HLA molecule subtypes by MBCs, in particular high HLA-A or B/C expression by MBC cells seems very specific in predicting the 5-year survival. We determined cut-off values for these HLA molecule clusters with high specificity, which might help identify patients with a favorable prognosis as prognosticators of a 5-year overall survival if their sensitivity is improved in larger prospective cohorts.
Goerdt L, Stefanovic A, Wirtz R, Karic U, Kohler M, Deutsch T In Vivo. 2025; 39(2):758-765.
PMID: 40010968 PMC: 11884484. DOI: 10.21873/invivo.13880.
Garrido M, Navarro-Ocon A, Ronco-Diaz V, Olea N, Aptsiauri N Genes (Basel). 2025; 15(12.
PMID: 39766811 PMC: 11675875. DOI: 10.3390/genes15121542.
Breast cancer, viruses, and human leukocyte antigen (HLA).
James L, Georgopoulos A Sci Rep. 2024; 14(1):16179.
PMID: 39003313 PMC: 11246526. DOI: 10.1038/s41598-024-65707-9.
Kaplan H, Pazarci P ACS Omega. 2024; 9(6):6658-6662.
PMID: 38371775 PMC: 10870381. DOI: 10.1021/acsomega.3c07624.